Effects of prime-boost strategies on the protective efficacy and immunogenicity of a PLGA (85:15)-encapsulated Chlamydia recombinant MOMP nanovaccine
Pathogens and Disease · 2024
DOI: 10.1093/femspd/ftae004 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pathogens and Disease, 2024. Verfasst von Rajnish Sahu und 5 weiteren Autor:innen. Beteiligte Einrichtung: Center for NanoBiotechnology Research, Department of Biological Sciences, 1627 Harris Way, Alabama State University, Montgomery AL, 36104, United Sta…. Hauptthemen laut MEDLINE: Bacterial Vaccines, Mice, Inbred BALB C, Chlamydia muridarum, Cytokines. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 91 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS, NIGMS NIH HHS, National Science Foundation.
Abstract (Originalsprache)
To begin to optimize the immunization routes for our reported PLGA-rMOMP nanovaccine [PLGA-encapsulated Chlamydia muridarum (Cm) recombinant major outer membrane protein (rMOMP)], we compared two prime-boost immunization strategies [subcutaneous (SC) and intramuscular (IM-p) prime routes followed by two SC-boosts)] to evaluate the nanovaccine-induced protective efficacy and immunogenicity in female BALB/c mice. Our results showed that mice immunized via the SC and IM-p routes were protected against a Cm genital challenge by a reduction in bacterial burden and with fewer bacteria in the SC mice. Protection of mice correlated with rMOMP-specific Th1 (IL-2 and IFN-γ) and not Th2 (IL-4, IL-9, and IL-13) cytokines, and CD4+ memory (CD44highCD62Lhigh) T-cells, especially in the SC mice. We also observed higher levels of IL-1α, IL-6, IL-17, CCL-2, and G-CSF in SC-immunized mice. Notably, an increase of cytokines/chemokines was seen after the challenge in the SC, IM-p, and control mice (rMOMP and PBS), suggesting a Cm stimulation. In parallel, rMOMP-specific Th1 (IgG2a and IgG2b) and Th2 (IgG1) serum, mucosal, serum avidity, and neutralizing antibodies were more elevated in SC than in IM-p mice. Overall, the homologous SC prime-boost immunization of mice induced enhanced cellular and antibody responses with better protection against a genital challenge compared to the heterologous IM-p.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Center for NanoBiotechnology Research, Department of Biological Sciences, 1627 Harris Way, Alabama State University, Montgomery AL, 36104, United States.
- US Army Medical Research Institute of Infectious Diseases, Unit 8900, DPO, AE, Box 330, 09831, United States.
- Instituto de Inmunología, Genética y Metabolismo (INIGEM). CONICET. AV. Cordoba 2351, Universidad de Buenos Aires, Buenos Aires, C1120AAR, Argentina.
ORCID-Profile: Rajnish Sahu
Förderung
- NIAID NIH HHS
- NIGMS NIH HHS
- National Science Foundation
- NIH HHS
- National Institutes of Health
Zitieren
APA
Sahu, R., Verma, R., Egbo, T. E., Giambartolomei, G. H., Singh, S. R., & Dennis, V. A. (2024). Effects of prime-boost strategies on the protective efficacy and immunogenicity of a PLGA (85:15)-encapsulated Chlamydia recombinant MOMP nanovaccine. Pathogens and Disease. https://doi.org/10.1093/femspd/ftae004
Vancouver
Sahu R, Verma R, Egbo TE, Giambartolomei GH, Singh SR, Dennis VA. Effects of prime-boost strategies on the protective efficacy and immunogenicity of a PLGA (85:15)-encapsulated Chlamydia recombinant MOMP nanovaccine. Pathogens and Disease. 2024. doi:10.1093/femspd/ftae004
BibTeX
@article{Sahu2024,
author = {Sahu, Rajnish and Verma, Richa and Egbo, Timothy E and Giambartolomei, Guillermo H and Singh, Shree R and Dennis, Vida A},
title = {Effects of prime-boost strategies on the protective efficacy and immunogenicity of a PLGA (85:15)-encapsulated Chlamydia recombinant MOMP nanovaccine},
journal = {Pathogens and Disease},
year = {2024},
doi = {10.1093/femspd/ftae004}
}
EUVIMED